BS_AWH9757B
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 31.110381077529563
- age_years
- 8.507
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.408
- G2M_CHECKPOINT+0.392
- PANCREAS_BETA_CELLS+0.315
- SPERMATOGENESIS+0.303
- MITOTIC_SPINDLE+0.293
- MYC_TARGETS_V1+0.224
- MYC_TARGETS_V2+0.117
- KRAS_SIGNALING_DN+0.098
- HEDGEHOG_SIGNALING+0.082
- UV_RESPONSE_UP+0.036
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.651
- INTERFERON_GAMMA_RESPONSE-0.575
- IL6_JAK_STAT3_SIGNALING-0.414
- TNFA_SIGNALING_VIA_NFKB-0.369
- IL2_STAT5_SIGNALING-0.354
- APOPTOSIS-0.353
- P53_PATHWAY-0.346
- ALLOGRAFT_REJECTION-0.318
- INFLAMMATORY_RESPONSE-0.296
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.294
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WH5HDE0A | medulloblastoma | — | 0.918 |
| 2 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.903 |
| 3 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.901 |
| 4 | BS_FEV5A0HN | high-grade glioma | — | 0.895 |
| 5 | 91648 | EPN | Supratentorial EPN | 0.888 |
| 6 | BS_AM70R8RG | medulloblastoma | — | 0.887 |
| 7 | BS_45J79YTF | high-grade glioma | — | 0.886 |
| 8 | TCGA-D8-A13Y-01A-11R-A115-07 | — | B | 0.884 |
| 9 | DRR168561 | — | — | 0.883 |
| 10 | SRR13780251 | — | cohortSC | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.408 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.392 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.315 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.303 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.224 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.117 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.098 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.082 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.036 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.027 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.026 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.026 | Idelalisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.008 | Remibrutinib | — uncovered |